Cumberland Pharmaceuticals Inc.

CPIX

US2307701092

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
1.59 ^USD	+3.25%		+3.92%	-11.26%

May. 07	Transcript : Cumberland Pharmaceuticals Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07	Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q1 Revenue $8.5M	MT

Cumberland Pharmaceuticals Inc. Provides Revenue Guidance for 2021

August 10, 2021 at 04:30 pm EDT

Cumberland Pharmaceuticals Inc. provides revenue guidance for 2021. The company expects to deliver another year of meaningful revenue growth in 2021.

Latest news about Cumberland Pharmaceuticals Inc.

Transcript : Cumberland Pharmaceuticals Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q1 Revenue $8.5M	May. 07	MT
Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010.	Mar. 13	CI
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Transcript : Cumberland Pharmaceuticals Inc., 2023 Earnings Call, Mar 05, 2024	Mar. 05
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Cumberland Pharmaceuticals Seeks Acquisitions	Nov. 07	CI
Transcript : Cumberland Pharmaceuticals Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 EPS $0.02	Nov. 07	MT
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 Revenue $10.1M	Nov. 07	MT
Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010.	Nov. 06	CI
Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age	23-10-10	CI
Cumberland Pharmaceuticals Inc. Announces New Publication in Antimicrobial Agents and Chemotherapy Detaining the Safety and Pharmacokinetics of Vibativ Injection in Children 2 to 17 Years of Age	23-10-10	CI
Correction to SEC Fines Article	23-09-27	DJ
SEC Fines 5 Public Companies, Insiders Over Reporting Failures	23-09-27	DJ
SEC Charges Corporate Insiders for Failing to Timely Report Transactions and Holdings	23-09-27	CI
Cumberland Pharmaceuticals Inc. Enters into A New Revolving Credit Loan Agreement with Pinnacle Bank	23-09-06	CI
Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010.	23-08-11	CI
Transcript : Cumberland Pharmaceuticals Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q2 EPS $0.16	23-08-08	MT
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q2 Revenue $10.9M	23-08-08	MT
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Cumberland Pharmaceuticals Inc. Presents Results from an Interim Analysis for the FIGHT DMD Trial	23-06-30	CI
Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric Drugs	23-06-26	CI

Chart Cumberland Pharmaceuticals Inc.

Duration

Period

More charts

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CUMBERLAND PHARMACEUTICALS INC.	-11.26%	21.83M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.09%	43.27B
OTSUKA HOLDINGS CO., LTD.	+26.13%	22.92B
SANDOZ GROUP AG	+19.22%	15.43B
CIPLA LIMITED	+13.51%	12.95B
ZYDUS LIFESCIENCES LIMITED	+44.01%	11.83B
ONO PHARMACEUTICAL CO., LTD.	-6.06%	6.91B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.26%	5.55B

Generic Pharmaceuticals